Pharma News

Zydus Lifesciences has achieved a significant regulatory milestone as the U.S. Food and Drug Administration (USFDA) granted Orphan Drug Designation (ODD) to its novel molecule Desidustat for the treatment of Sickle Cell Disease (SCD). The designation highlights the growing recognition of the urgent need for new and effective therapies in this rare and challenging condition.

Low back pain (LBP) is one of the most common health problems worldwide, affecting people of all ages and placing a heavy burden on healthcare systems. Many patients experience persistent discomfort that interferes with work, sleep, and daily activities. Yet in most cases, doctors cannot identify a clear structural cause, making long-term treatment difficult.

Emcure Pharmaceuticals Ltd. announced robust financial results for the third quarter of the 2025-26 fiscal year, marking significant growth across both domestic and international businesses. The company reported a notable rise in profitability and topline performance, underpinned by diversified portfolio strength and strategic initiatives.

As the world observes World Neglected Tropical Diseases (NTD) Day 2026, global health leaders are celebrating major gains against neglected diseases while raising serious concern over declining financial support. The World Health Organization (WHO) has warned that a 41% decline in NTD aid between 2018 and 2023 threatens to stall or reverse years of progress.

Novo Nordisk has reported encouraging Phase 3 results for CagriSema, its investigational once-weekly treatment for adults with type 2 diabetes, positioning the therapy as a strong next-generation option in an increasingly competitive metabolic disease market. The findings come from the REIMAGINE-2 trial, where the combination therapy delivered superior glycaemic control and weight reduction compared to semaglutide alone.